Literature DB >> 26515584

Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.

Rui M Gil da Costa1,2, Paula A Oliveira3,4, Carmen Vasconcelos-Nóbrega5,6, Regina Arantes-Rodrigues4, Rosário Pinto-Leite7, Aura A Colaço3,8, Luis F de la Cruz9, Carlos Lopes2.   

Abstract

Cytokeratins (CKs) 14 and 20 are promising markers for diagnosing urothelial lesions and for studying their prognosis and histogenesis. This work aimed to study the immunohistochemical staining patterns of CK14/20 during multistep carcinogenesis leading to papillary bladder cancer in a rat model. Thirty female Fischer 344 rats were divided into three groups: group 1 (control); group 2, which received N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) for 20 weeks plus 1 week without treatment; and group 3, which received BBN for 20 weeks plus 8 weeks without treatment. Bladder lesions were classified histologically. CK14 and CK20 immunostaining was assessed according to its distribution and intensity. In control animals, 0-25% of basal cells and umbrella cells stained positive for CK14 and CK20 respectively. On groups 2 and 3, nodular hyperplastic lesions showed normal CK20 and moderately increased CK14 staining (26-50% of cells). Dysplasia, squamous metaplasia, papilloma, papillary tumours of low malignant potential and low- and high-grade papillary carcinomas showed increased CK14 and CK20 immunostaining in all epithelial layers. Altered CK14 and CK20 expression is an early event in urothelial carcinogenesis and is present in a wide spectrum of urothelial superficial neoplastic and preneoplastic lesions.
© 2015 The Authors. International Journal of Experimental Pathology © 2015 International Journal of Experimental Pathology.

Entities:  

Keywords:  CK14; CK20; bladder cancer; multistep carcinogenesis; rat; stem cell

Mesh:

Substances:

Year:  2015        PMID: 26515584      PMCID: PMC4693561          DOI: 10.1111/iep.12145

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  24 in total

Review 1.  Review: BBN as an urothelial carcinogen.

Authors:  C Vasconcelos-Nóbrega; A Colaço; C Lopes; P A Oliveira
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

2.  Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.

Authors:  Mahul B Amin; Kiril Trpkov; Antonio Lopez-Beltran; David Grignon
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

Review 3.  Animal models of urinary bladder cancer and their application to novel drug discovery.

Authors:  Paula A Oliveira; Regina Arantes-Rodrigues; Carmen Vasconcelos-Nóbrega
Journal:  Expert Opin Drug Discov       Date:  2014-03-26       Impact factor: 6.098

4.  Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas.

Authors:  P Harnden; J Southgate
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

5.  Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.

Authors:  Allison Edgecombe; Bich N Nguyen; Bojana Djordjevic; Eric C Belanger; Kien T Mai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-05

Review 6.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

7.  Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.

Authors:  Kien T Mai; Trevor A Flood; Phillip Williams; Zuzana Kos; Eric C Belanger
Journal:  Virchows Arch       Date:  2013-08-04       Impact factor: 4.064

8.  CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.

Authors:  Yong-kang Ye; Xue-cheng Bi; Hui-chan He; Zhao-dong Han; Qi-shan Dai; Yu-xiang Liang; Guo-hua Zeng; Wei-jun Qin; Zhi-nan Chen; Wei-de Zhong
Journal:  Clin Exp Med       Date:  2010-01-13       Impact factor: 3.984

9.  Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies.

Authors:  Shazia Mumtaz; Atif Ali Hashmi; Sheema H Hasan; Muhammad Muzzammil Edhi; Mehmood Khan
Journal:  Int Arch Med       Date:  2014-07-26

10.  Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma.

Authors:  Kunyoo Shin; Agnes Lim; Justin I Odegaard; Jared D Honeycutt; Sally Kawano; Michael H Hsieh; Philip A Beachy
Journal:  Nat Cell Biol       Date:  2014-04-20       Impact factor: 28.824

View more
  3 in total

1.  Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis.

Authors:  Yun-Peng Li; Xiao-Peng Jia; Yu-Qing Jiang; Wei Wang; Yun-Liang Wang; Xiu-Li Wang; Yue-Xian Guo
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-19

Review 2.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

Review 3.  Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy.

Authors:  Ana Mafalda Rasteiro; Eva Sá E Lemos; Paula A Oliveira; Rui M Gil da Costa
Journal:  Vet Sci       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.